Opendata, web and dolomites

STRATEGY-CKD SIGNED

System omics to unravel the gut-kidney axis in Chronic Kidney Disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRATEGY-CKD project word cloud

Explore the words cloud of the STRATEGY-CKD project. It provides you a very rough idea of what is the project "STRATEGY-CKD" about.

50    women    biology    deaths    patient    mechanistic    basic    omics    contributor    train    trained    links    samples    training    animals    programs    personal    extremely    industrial    patients    collaborations    treatment    unravelling    stimulate    chronic    environments    industry    bioinformatics    socio    complementary    builds    genesis    extend    translation    bridges    career    prevalent    innovative    therapeutic    multidisciplinary    ckd    metabolomics    generate    skills    ongoing    risk    kidney    unravel    young    cvd    scientists    pathogenesis    scientific    technological    academia    functional    link    strategy    system    burden    insights    business    microbi    disciplinary    vitro    diseases    teams    microbiome    evolution    methodologically    successfully    peptid    investigators    services    gut    academic    economic    bacterial    broadly    purpose    molecular    integrating    prote    intestinal    excellent    omic    cardiovascular    context    cultur    nearly    caused    therapies    disease    axis    models    outcome    exposure    entrepreneurs    clinical   

Project "STRATEGY-CKD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT GENT 

Organization address
address: SINT PIETERSNIEUWSTRAAT 25
city: GENT
postcode: 9000
website: http://www.ugent.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 3˙363˙591 €
 EC max contribution 3˙363˙591 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT GENT BE (GENT) coordinator 256˙320.00
2    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 531˙239.00
3    RD NEPHROLOGIE SAS FR (MONTPELLIER) participant 274˙802.00
4    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 274˙802.00
5    UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI IT (CASERTA) participant 261˙499.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 256˙320.00
7    VIB BE (ZWIJNAARDE - GENT) participant 256˙320.00
8    MOSAIQUES DIAGNOSTICS GMBH DE (HANNOVER) participant 252˙788.00
9    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 252˙788.00
10    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 252˙788.00
11    INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ ES (MADRID) participant 250˙904.00
12    IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON EL (ATHINA) participant 243˙017.00

Map

 Project objective

System omics to unravel the gut-kidney axis in Chronic Kidney Disease: There is a great need for multi-disciplinary and methodologically well trained scientists in order to unravel complex diseases. Chronic kidney disease (CKD), which is more prevalent in women, and its high risk for cardiovascular disease (CVD) with nearly 50% of all deaths in CKD patients caused by CVD, is such a complex disease and its socio-economic burden is extremely high. STRATEGY-CKD will in this context focus on the gut-kidney axis and the role of the intestinal microbiome as important contributor to the genesis and evolution of CVD in CKD and as possible therapeutic target to improve outcome of CKD patients. For this purpose, 10 leading multidisciplinary academic and 3 industrial investigators and their teams will train young researchers in (1) excellent scientific skills, integrating technological skills [in vitro, bacterial and animals molecular and functional studies, state-of-the-art omic (cultur-, microbi, peptid-, prote-, metabolomics) approaches, bioinformatics, systems biology] in clinical/mechanistic knowledge to generate innovative insights triggering the pathogenesis and treatment of CKD related CVD; (2) Excellent complementary skills in personal and career development as well as business training required to extend beyond scientific research; and (3) exposure to both academic and non-academic environments, required to build bridges between researchers and entrepreneurs and support the future translation of research findings in innovative therapies and services. STRATEGY-CKD builds on already available advanced technology, models and patient samples, and established collaborations. STRATEGY-CKD links to ongoing European programs among partners of the consortium. STRATEGY-CKD will stimulate the development of young, broadly-trained scientists able to successfully link basic to clinical research in academia as well as in industry unravelling complex diseases such as CVD-CKD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRATEGY-CKD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRATEGY-CKD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

MLFPM2018 (2019)

Machine Learning Frontiers in Precision Medicine

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More